Skip to main content
VKTX
NASDAQ Life Sciences

Viking's Obesity Trials Fully Enrolled, Oral VK2735 Phase 3 Set for Q4

Tom Rudovsky · Reported by PR Newswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$33.27
Mkt Cap
$3.881B
52W Low
$22.959
52W High
$43.15
52W Position info
45% above low
Off High info
23% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

VKTX sits 45% above its 52-week low of $22.959.

Summary

Viking Therapeutics reported Q2 2026 results with a strong cash position of $502 million and a milder-than-expected net loss. The Phase 3 VANQUISH 1 and 2 trials for subcutaneous VK2735 are fully enrolled and advancing, with top-line data expected to be a major catalyst. Oral VK2735 Phase 3 initiation is planned for Q4 2026, positioning it as a potential first-in-class oral dual GLP-1/GIP agonist. Maintenance dosing data for VK2735 is due this quarter, which could differentiate the drug for long-term weight management. The company also initiated a Phase 1 trial for amylin agonist VK3019 and appointed a new chief medical officer, signaling infrastructure build-out. This follows a prior 8-K disclosing a dispute with Ligand over VK2809, but the obesity pipeline remains the primary value driver.

Updates

  1. · Wiseek News — Canaccord raised its price target to $114 from $107.

At the time of this announcement, VKTX was trading at $33.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $22.96 to $43.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

VKTX - Latest Insights

VKTX
Oct 29, 2026, 10:43 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $27.18
Real-time Price: $26.75 info
Change: -$0.435 (-2%) info
Market Cap: $3.429B info
VKTX
Oct 28, 2026, 5:40 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $24.70
Real-time Price: $26.75 info
Change: +$2.04 (+8%) info
Market Cap: $3.429B info
VKTX
Oct 28, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $24.38
Real-time Price: $26.75 info
Change: +$2.37 (+10%) info
Market Cap: $3.429B info
VKTX
Oct 28, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $25.41
Real-time Price: $26.75 info
Change: +$1.34 (+5%) info
Market Cap: $3.429B info
VKTX
Sep 28, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.28
Real-time Price: $26.75 info
Change: -$6.54 (-20%) info
Market Cap: $3.429B info